

NEBRASKA MEDICAID AD HOC FEE SCHEDULE

**This fee schedule is subject to change, as further Center of Medicare & Medicaid's (CMS) guidance occurs.
The updates in this version are reflected in red.**

COVID-19 CODES

CODE	MOD	DESCRIPTION	PA	COMMENTS	COPAY	MEDICAID ALLOWABLE EFFECTIVE FOR CLAIMS WITH DOS THROUGH TO	MEDICAID ALLOWABLE EFFECTIVE FOR CLAIMS WITH DOS ON OR AFTER
						3/14/2021	3/15/2021
0031A		JANSSEN SINGLE DOSE: IMMUNIZATION ADMINISTRATION BY INTRAMUSCULAR INJECTION OF SEVERE ACUTE RESPIRAT		RATE CHANGE \$36.94 Effective 1/1/2022		\$28.39	\$37.25
0034A		JANSEN COVID-19 VACCINE ADMINISTRATION -BOOSTER		RATE CHANGE \$36.94 Effective 1/1/2022			\$37.25 Effective 11/2/2021
0041A		Novavax Covid-19 Vaccine, Adjuvanted Administration – First Dose "Other" ADM SARSCOV2 5MCG/0.5ML 1ST					\$36.94 Effective 7/13/2022
0042A		Novavax Covid-19 Vaccine, Adjuvanted Administration – Second Dose "Other" ADM SARSCOV2 5MCG/0.5ML 2ND					\$36.94 Effective 7/13/2022
0051A		Pfizer-BioNTech Covid-19 Vaccine (Ready to Use) Administration - First dose					\$36.94 Effective 12/27/2021
0052A		Pfizer-BioNTech Covid-19 Vaccine (Ready to Use) Administration - Second dose					\$36.94 Effective 12/27/2021
0053A		Pfizer-BioNTech Covid-19 Vaccine (Ready to Use) Administration - Third dose					\$36.94 Effective 12/27/2021
0054A		Pfizer-BioNTech Covid-19 Vaccine (Ready to Use) Administration - Booster					\$36.94 Effective 12/27/2021
0071A		Pfizer-BioNTech Covid-19 Pediatric Vaccine - Administration - First dose		RATE CHANGE \$36.94 Effective 1/1/2022			\$37.25 Effective 11/2/2021
0072A		Pfizer-BioNTech Covid-19 Pediatric Vaccine - Administration - Second dose		RATE CHANGE \$36.94 Effective 1/1/2022			\$37.25 Effective 11/2/2021
0081A		Pfizer-6 months through 4 years: Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use - 1st Dose					\$36.94 Effective 6/17/2022
0082A		Pfizer-6 months through 4 years: Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use - 2nd Dose					\$36.94 Effective 6/17/2022
0083A		Pfizer-6 months through 4 years: Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use - 3rd Dose					\$36.94 Effective 6/17/2022
0091A		MODERNA-Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; first dose, when administered to individuals 6 through 11 years: ADM SARSCOV2 50 MCG/.5 ML1ST					\$36.94 Effective 6/17/2022
0092A		MODERNA- Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; second dose, when administered to individuals 6 through 11 years: ADM SARSCOV2 50 MCG/ .5 ML2ND					\$36.94 Effective 6/17/2022
0093A		MODERNA-Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; third dose, when administered to individuals 6 through 11 years: : ADM SARSCOV2 50 MCG/.5 ML3RD					\$36.94 Effective 6/17/2022
0111A		Moderna-6 months through 5 years: Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP spike protein preservative free, 25 mcg/0.25 mL dosage, for intramuscular use - 1st Dose, ADM SARSCOV2 25MCG/0.25ML1ST					\$36.94 Effective 6/17/2022

0112A		Moderna-6 months through 5 years: Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP spike protein preservative free, 25 mcg/0.25 mL dosage, for intramuscular use - 2nd Dose, ADM SARSCOV2 25MCG/0.25ML2ND					\$36.94 Effective 6/17/2022
0113A		Moderna: Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; third dose, ADM SARSCOV2 25MCG/0.25ML3RD					\$36.94 Effective 6/17/2022
0124A		PFIZER-BIONTECH COVID-19 VACCINE, BIVALENT (GRAYCAP) ADMINISTRATION BOOSTER DOSE-ADM SARSCV2 BVL 30MCG/.3ML B				CODE NOT ACTIVE DURING THIS TIME	\$36.94 EFFECTIVE 08/31/2022
0134A		MODERNA COVID-19 VACCINE, BIVALENT (AGED 18 YEARS AND OLDER) (DARK BLUE CAP WITH GRAY BORDER) ADMINISTRATION BOOSTER DOSE ADM SARSCV2 BVL 50MCG/.5ML B				CODE NOT ACTIVE DURING THIS TIME	\$36.94 EFFECTIVE 08/31/2022
0154A		PFIZER-BIONTECH COVID-19 VACCINE, BIVALENT PRODUCT (AGED 5 YEARS THROUGH 11 YEARS) (ORANGE CAP) ADMINISTRATION-BOOSTER DOSE ADM SARSCV2 BVL 10MCG/.2ML B				CODE NOT ACTIVE DURING THIS TIME	\$36.94 EFFECTIVE 10/12/2022
0073A		IMMUNIZATION ADMINISTRATION BY INTRAMUSCULAR INJECTION OR SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) (CORONAVIRUS DISEASE)					\$36.94 Effective 1/4/2022
0074A		PFIZER-BIONTECH COVID-19 PEDIATRIC VACCINE (ORANGE CAP) ADMINISTRATION BOOSTER-ADM SARSCV2 10MCG TRS-SUCRB					\$36.94 Effective 5/17/2022
0094A		MODERNA-ADM SARSCOV2 50MCG/0.5 MLBST					\$36.94 Effective 3/29/2022
0004A		Pfizer-BioNTech Covid-19 Vaccine Administration – Booster				RATE CHANGE \$36.94 Effective 1/1/2022	\$37.25 Effective 9/22/2021
0064A		Moderna Covid-19 Vaccine (Low Dose) Administration - Booster				RATE CHANGE \$36.94 Effective 1/1/2022	\$37.25 Effective 10/20/2021
0003A		PFIZER BIONTECH COVID-19 ADM SARSCOV2 30MCG/0.3ML 3RD DOSE				RATE CHANGE \$36.94 Effective 1/1/2022	\$37.25 Effective 8/12/2021
0013A		MODERNA COVID-19 ADM SARSCOV2 100MCG/0.5ML 3RD DOSE: EFFECTIVE FOR AGE 12 AND OLDER 6-17-2022				RATE CHANGE \$36.94 Effective 1/1/2022	\$37.25 Effective 8/12/2021
M0201		COVID-19 VACCINE ADMINISTRATION INSIDE A PATIENT'S HOME				RATE CHANGE \$33.05 Effective 1/1/2022	\$32.50 Effective 8/6/2021
M0220		INJECTION, TIXAGENIVIMAB AND CILGAVIMAB, FOR THE PRE-EXPOSURE PROPHYLAXIS ONLY, FOR CERTAIN ADULTS AND PEDIATRIC INDIVIDUALS; INJECTION AND ADMINISTRATION MONITORING.					\$135.31 Effective 12/8/2021
M0221		INJECTION, TIXAGENIVIMAB AND CILGAVIMAB, FOR THE PRE-EXPOSURE PROPHYLAXIS ONLY, FOR CERTAIN ADULTS AND PEDIATRIC INDIVIDUALS; INJECTION AND ADMINISTRATION MONITORING IN THE HOME OR RESIDENCE					\$225.36 Effective 12/8/2021
M0222		INTRAVENOUS INJECTION, BEBTELOVIMAB. INCLUDES INJECTION AND POST ADMINISTRATION MONITORING					\$350.50 Effective 2/11/2022
M0223		INTRAVENOUS INJECTION, BEBTELOVIMAB. INCLUDES INJECTION AND POST ADMINISTRATION MONITORING IN THE HOME OR RESIDENCE; THIS INCLUDES A BENEFICIARY'S HOME THAT HAS BEEN MADE PROVIDER-BASED TO THE HOSPITAL DURING THE COVID-19 PUBLIC HEALTH EMERGENCY					\$550.50 Effective 2/11/2022

Q0221		INJECTION, TIXAGEVIMAB AND CILGAVIMAB, FOR THE PRE-EXPOSURE PROPHYLAXIS ONLY, FOR CERTAIN ADULTS AND PEDIATRIC INDIVIDUALS (12 YEARS OF AGE AND OLDER WEIGHING AT LEAST 40kg) WITH NO KNOWN SARS-COV-2 EXPOSURE, WHO EITHER HAVE MODERATE TO SEVERELY COMPROMISED IMMUNE SYSTEMS OR FOR WHOM VACCINATION WITH ANY AVAILABLE COVID-19 VACCINE IS NOT RECOMMENDED DUE TO A HISTORY OF SEVERE ADVERSE REACTION TO A COVID-19 VACCINE(S) AND/OR COVID-19 VACCINE COMPONENT(S) 600mg				Not covered while federally supplied Effective 2/24/2022
Q0222		INJECTION, BEBTELOVIAMAB, 175MG				Not covered while federally supplied Effective 2/11/2022
M0240		INTRAVENOUS INFUSION OR SUBCUTANEOUS INJECTION, CASIRIVIMAB AND IMDEVIMAB INCLUDES INFUSION OR INJECTION, AND POST ADMINISTRATION MONITORING, SUBSEQUENT REPEAT DOSES.	RATE CHANGE \$404.92 Effective 12/8/2021			\$404.78 Effective 7/30/2021
M0241		INTRAVENOUS INFUSION OR SUBCUTANEOUS INJECTION, CASIRIVIMAB AND IMDEVIMAB INCLUDES INFUSION OR INJECTION, AND POST ADMINISTRATION MONITORING IN THE HOME OR RESIDENCE, SUBSEQUENT REPEAT DOSES.	RATE CHANGE \$674.52 Effective 12/8/2021			\$674.94 Effective 7/30/2021
M0244		INTRAVENOUS INFUSION, CASIRIVIMAB AND IMDEVIMAB INCLUDES INFUSION AND POST ADMINISTRATION MONITORING	RATE CHANGE \$674.52 Effective 12/8/2021			\$674.94 Effective 5/6/2021
M0246		INTRAVENOUS INFUSION, BAMLANIVIMAB AND ETESEVIMAB, INCLUDES INFUSION AND POST ADMINISTRATION MONITORING IN THE HOME OR RESIDENCE DURING COVID-19 PHASE	RATE CHANGE \$674.52 Effective 12/8/2021			\$674.94 Effective 5/6/2021
M0247		INTRAVENOUS INFUSION, SOTROVIMAB, INCLUDES INFUSION AND POST ADMINISTRATION MONITORING	RATE CHANGE \$404.92 Effective 12/8/2021			\$404.78 Effective 5/26/2021
M0248		INTRAVENOUS INFUSION, SOTROVIMAB, INCLUDES INFUSION AND POST ADMINISTRATION MONITORING IN THE HOME OR RESIDENCE	RATE CHANGE \$674.52 Effective 12/8/2021			\$674.94 Effective 5/26/2021
M0249		INTRAVENOUS INFUSION, TOCILIZUMAB, FOR HOSPITALIZED ADULTS AND PEDIATRIC PATIENTS.. 1ST DOSE	RATE CHANGE \$404.92 Effective 12/8/2021			\$404.78 Effective 6/24/2021
M0250		INTRAVENOUS INFUSION, TOCILIZUMAB, FOR HOSPITALIZED ADULTS AND PEDIATRIC PATIENTS.. 2ND DOSE	RATE CHANGE \$404.92 Effective 12/8/2021			\$404.78 Effective 6/24/2021
Q0247		INJECTION, SOTROVIMAB, 500mg				\$2,394.00 Effective 5/26/2021
Q0249		INJECTION, TOCILIZUMAB, FOR HOSPITALIZED ADULTS AND PEDIATRIC PATIENTS.. WITH COVID-19...ECMO ONLY 1 MG				\$6.57 Effective 6/24/2021
D0606		MOLECULAR TESTING FOR A PUBLIC HEALTH RELATED PATHOGEN, INCLUDING CORONA VIRUS	RATE CHANGE \$56.44 EFFECTIVE 7/1/2022			\$51.31
D0171		RE-EVALUATION, POST-OPERATIVE OFFICE VISIT				\$17.95 Effective 7/1/2022
D1701		PFIZER 1ST DOSE: IMMUNIZATION ADMINISTRATION BY INTRAMUSCULAR INJECTION OF SEVERE ACUTE RESPIRATORY SYNDROME VIRUS 2	RATE CHANGE \$40.98 EFFECTIVE 7/1/2022			\$37.25
D1702		PFIZER 2ND DOSE: IMMUNIZATION ADMINISTRATION BY INTRAMUSCULAR INJECTION OF SEVERE ACUTE RESPIRATORY SYNDROME VIRUS 2	RATE CHANGE \$40.98 EFFECTIVE 7/1/2022			\$37.25
D1703		MODERNA 1ST DOSE: IMMUNIZATION ADMINISTRATION BY INTRAMUSCULAR INJECTION OF SEVERE ACUTE RESPIRATORY SYNDROME VIRUS 2	RATE CHANGE \$40.98 EFFECTIVE 7/1/2022			\$37.25
D1704		MODERNA 2ND DOSE: IMMUNIZATION ADMINISTRATION BY INTRAMUSCULAR INJECTION OF SEVERE ACUTE RESPIRATORY SYNDROME VIRUS 2	RATE CHANGE \$40.98 EFFECTIVE 7/1/2022			\$37.25
D1707		JANSSEN SINGLE DOSE: IMMUNIZATION ADMINISTRATION BY INTRAMUSCULAR INJECTION OF SEVERE ACUTE RESPIRATORY SYNDROME VIRUS 2	RATE CHANGE \$40.98 EFFECTIVE 7/1/2022			\$37.25
D1708		Pfizer-biontech covid-19 vaccine administration - third dose				\$40.98 Effective 7/1/2022
D1709		Pfizer-biontech covid-19 vaccine administration - booster dose				\$40.98 Effective 7/1/2022
D1710		Moderna covid-19 vaccine administration - third dose				\$40.98 Effective 7/1/2022
D1711		Moderna covid-19 vaccine administration - booster dose				\$40.98 Effective 7/1/2022
D1712		Janssen covid-19 vaccine administration - booster dose				\$40.98 Effective 7/1/2022
D1713		Pfizer-biontech covid-19 vaccine administration tris-sucrose pediatric - first dose				\$40.98 Effective 7/1/2022

D1714		Pfizer-biontech covid-19 vaccine administration tris-sucrose pediatric - second dose				\$40.98 Effective 7/1/2022
D9995		Teledentistry - Synchronous; Real-Time Encounter				\$0.00 Effective 3/1/2020
D9999		Unspecified Adjunctive procedure				\$15.92 Effective 7/1/2022
87426	QW	INFECTIOUS AGENT ANTIGEN DETECTION BY IMMUNOASSAY TECHNIQUE, (EG, ENZYME IMMUNOASSAY, ENZYME-LINKED IMMUNOSORBENT ASSAY,		COVID EMERGENCY PERIOD	\$35.33	
87428	QW	INFECTIOUS AGENT ANTIGEN DETECTION BY IMMUNOASSAY TECHNIQUE, (EG, ENZYME IMMUNOASSAY ENZYME-LINKED, IMMUNOSORBENT ASSAY, FLUORESC		COVID EMERGENCY PERIOD	\$63.59	\$30.94 EFFECTIVE 1/1/2022
87635	QW	AMPLIFIED DNA OR RNA PROBE DETECTION OF SARS CORONORIVUS		COVID EMERGENCY PERIOD	\$51.31	
M0243		INTRAVENOUS INFUSION, CASIRIVIMAB AND IMDEVIMAB INCLUDES INFUSION AND POST ADMINISTRATION MONITORING		RATE CHANGE \$404.92 Effective 12/08/2021	\$309.60	\$404.78 Effective 5/6/2021
M0245		INTRAVENOUS INFUSION, BAMLANIVIMAB AND ETESEVIMAB, INCLUDES INFUSION AND POST ADMINISTRATION MONITORING		RATE CHANGE \$404.92 Effective 12/08/2021	\$309.60	\$404.78 Effective 5/6/2021
C9803		HOSPITAL OUTPATIENT CLINIC VISIT SPECIMEN COLLECTION FOR (SARS-COV-2) (COVID-19), ANY SPECIMEN SOURCE		COVID EMERGENCY PERIOD	\$23.00	
G2023		SPECIMEN COLLECTION FOR COVID-19, ANY SPECIMEN SOURCE		COVID EMERGENCY PERIOD	\$23.46	
G2024		SPECIMEN COLLECTION FOR COVID-19, FROM AN INDIVIDUAL IN A SNF OR LABORATORY ON BEHALF OF A HOME HEALTH AGENCY, ANY SPECIMEN SOURCE		COVID EMERGENCY PERIOD	\$25.46	
U0001		CDC 2019 NOVEL CORONAVIRUS (2019-NCOV) REAL-TIME RT-PCR DIAGNOSTIC PANEL		COVID EMERGENCY PERIOD	\$35.92	
U0002		NON-CDC SARS-COV-2/2019-NCOV (COVID-19)		COVID EMERGENCY PERIOD	\$51.31	
U0002	QW	NON-CDC SARS -COV-2/2019 -NCOV		COVID EMERGENCY PERIOD	\$51.31	
U0003		INFECTIOUS AGENT DETECTION BY DNA OR RNA;COVID-19,AMPLIFIED PROBE TECHNIQUE,HIGH THROUGHPUT TECHNOLOGIES AS DESCRIBED BY CMS-2020-01-R		COVID EMERGENCY PERIOD	\$100.00	\$75.00
U0004		COVID-19,ANY TECHNIQUE,MULTIPLE TYPES OR SUBTYPES,NON-CDC, MAKING USE OF HIGH THROUGHPUT TECHNOLOGIES AS DESRIBED BY CMS-2020-01-R		COVID EMERGENCY PERIOD	\$100.00	\$75.00
U0005		INFECTIOUS AGENT DETECTION BY NUCLEIC ACID (DNA OR RNA); SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) (CORONAVIRUS DISEASE YCO		COVID EMERGENCY PERIOD	\$25.00	
0001A		PFIZER 1ST DOSE: IMMUNIZATION ADMINISTRATION BY INTRAMUSCULAR INJECTION OF SEVERE ACUTE RESPIRATORY		RATE CHANGE \$36.94 Effective 1/1/2022	\$16.94	\$37.25
0002A		PFIZER 2ND DOSE: IMMUNIZATION ADMINISTRATION BY INTRAMUSCULAR INJECTION OF SEVERE ACUTE RESPIRATORY		RATE CHANGE \$36.94 Effective 1/1/2022	\$28.39	\$37.25
0011A		BY INTRAMUSCULAR INJECTION OF SEVERE ACUTE RESPIRATORY: EFFECTIVE FOR AGE 12 AND OLDER 6/17/2022		RATE CHANGE \$36.94 Effective 1/1/2022	\$16.94	\$37.25
0012A		MODERNA 2ND DOSE: IMMUNIZATION ADMINISTRATION BY INTRAMUSCULAR INJECTION OF SEVERE ACUTE RESPIRATORY: EFFECTIVE FOR AGE 12 AND OLDER 6/17/2022		RATE CHANGE \$36.94 Effective 1/1/2022	\$28.39	\$37.25
0202U		INFECTIOUS DISEASE(BACTERIAL OR VIRAL RESPIRATORY TRACT INFECTION), PATHOGEN-SPECIFIC NUCLEIC ACID (DNA OR RNA), 22 TARGETS INCLUDING SEVERE A		COVID EMERGENCY PERIOD	\$298.60	\$416.78 EFFECTIVE 1/1/2021
0223U		INFECTIOUS DISEASE(BACTERIAL OR VIRAL RESPIRATORY TRACT INFECTION), PATHOGEN-SPECIFIC NUCLEIC ACID (DNA OR RNA), 22 TARGETS INCLUDING SEVERE A		COVID EMERGENCY PERIOD	\$298.60	\$416.78 EFFECTIVE 1/1/2021
0224U		ANTIBODY, SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2(SARS-COV-2) (CORONAVIRUS DISEASE YCOVID-19"), INCLUDES TITER(S), WHEN PERFORMED (DO		COVID EMERGENCY PERIOD	\$42.13	
0225U		INFECTIOUS DISEASE (BACTERIAL OR VIRAL RESPIRATORY TRACT INFECTION) PATHOGEN-SPECIFIC DNA AND RNA, 21 TARGETS, INCLUDING SEVERE ACUTE RESPIRAT		COVID EMERGENCY PERIOD	\$298.60	\$416.78 EFFECTIVE 1/1/2021
0226U		SURROGATE VIRAL NEUTRALIZATION TEST (SVNT), SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) (CORONAVIRUS DISEASE YCOVID-19"), ELI		COVID EMERGENCY PERIOD	\$42.28	

0240U		INFECTIOUS DISEASE (VIRAL RESPIRATORY TRACT INFECTION),PATHOGEN-SPECIFIC RNA, 3 TARGETS (SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 SARS)		COVID EMERGENCY PERIOD		\$142.63	
0240U	QW	INFECTIOUS DISEASE (VIRAL RESPIRATORY TRACT INFECTION),PATHOGEN-SPECIFIC RNA, 3 TARGETS (SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 SARS)					\$142.63 EFFECTIVE 1/1/2022
0241U		INFECTIOUS DISEASE (VIRAL RESPIRATORY TRACT INFECTION),PATHOGEN-SPECIFIC RNA, 4 TARGETS (SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 SARS)		COVID EMERGENCY PERIOD		\$142.63	
0241U	QW	INFECTIOUS DISEASE (VIRAL RESPIRATORY TRACT INFECTION),PATHOGEN-SPECIFIC RNA, 4 TARGETS (SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 SARS)					\$142.63 EFFECTIVE 1/1/2022
86328		IMMUNOASSAY FOR INFECTIOUS AGENT ANTIBODY(IES), QUALITATIVE OR SEMIQUANTITATIVE, SINGLE STEP METHOD (EG, REAGENT STRIP); (SARS-COV-2)(COVID-19)		COVID EMERGENCY PERIOD		\$45.23	\$45.28 EFFECTIVE 1/1/2022
86328	QW	TEST FOR DETECTION OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 COVID-19					\$45.28 EFFECTIVE 1/1/2022
86408		SCREENING TEST FOR DETECTION OF SEVERE ACUTE RESPIRATORY SUNDROME CORONAVIRUS 2		COVID EMERGENCY PERIOD		\$42.13	
86409		MEASUREMENT OF NEUTRALIZING ANTIBODY TO SEVERE ACUTE RESPIRATORY SYNDROME CORONA		COVID EMERGENCY PERIOD		\$79.61	
86769		ANTIBODY; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2(SARS-COV-2) (COVID-19)		COVID EMERGENCY PERIOD		\$42.13	
87301		INFECTIOUS AGENT ANTIGEN DETECTION BY ENZYME IMMUNOASSAY TECHNIQUE, QUALITATIVE OR SEMIQUANTITATIVE, MULTIPLE STEP METHOD; ADENO VIRUS		COVID EMERGENCY PERIOD		\$11.98	
87426		INFECTIOUS AGENT ANTIGEN DETECTION BY IMMUNOASSAY TECHNIQUE,(EG, ENZYME IMMUNOASSAY YÉIA ", ENZYME-LINKED IMMUNOSORBENT ASSAY YÉLISA ", IMMUNOCH		COVID EMERGENCY PERIOD		\$35.33	
87428		INFECTIOUS AGENT ANTIGEN DETECTION BY IMMUNOASSAY TECHNIQUE,(EG, ENZYME IMMUNOASSAY YÉIA ", ENZYME-LINKED IMMUNOSORBENT ASSAY YÉLISA ", FLUORESC		COVID EMERGENCY PERIOD		\$63.59	\$30.94 EFFECTIVE 1/1/2022
87635		DETECTION OF SARS-COV-2 AND ANY PAN-CORONAVIRUS TYPES OR SUBTYPES;INFECTIOUS AGENT DETECTION BY NUCLEIC ACID(DNA OR RNA; SEVERE ACUTE RESPIRATOR		COVID EMERGENCY PERIOD		\$51.31	
87636		INFECTIOUS AGENT DETECTION BY NUCLEIC ACID (DNA OR RNA); SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) (CORONAVIRUS DISEASE YCO		COVID EMERGENCY PERIOD		\$142.63	
87636	QW	DETECTION TEST BY MULTIPLEX AMPLIFIED PROBE TECHNIQUE FOR SEVERE ACUTE RESPIRATORY VIRUS					\$142.63 EFFECTIVE 1/1/2022
87637		INFECTIOUS AGENT DETECTION BY NUCLEIC ACID (DNA OR RNA); SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) (CORONAVIRUS DISEASE YCO		COVID EMERGENCY PERIOD		\$142.63	
87637	QW	DETECTION TEST BY MULTIPLEX AMPLIFIED PROBE TECHNIQUE FOR SEVERE ACUTE RESPIRATORY VIRUS					\$142.63 EFFECTIVE 1/1/2022
87811		INFECTIOUS AGENT DETECTION BY NUCLEIC ACID (DNA OR RNA); SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) (CORONAVIRUS DISEASE YCO		COVID EMERGENCY PERIOD		\$41.38	